{"prompt": "['AMC PROTOCOL SIGNATURE PAGE', 'I, Nestory Masalu, Principal Investigator at site Bugando Medical Centre agree to conduct and', 'follow this protocol: AMC Protocol #S007 - Longitudinal Quality of Life Study Among', 'Participants with AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre, in', 'Mwanza, Tanzania (Version 2.0, 20MAR2018), as written according to AMC, NCI, and', 'National Institute for Medical Research (NIMR) guidelines. I understand that no deviations from', 'the protocol eligibility criteria or waivers for protocol deviations will be permitted.', 'Signature', 'Date (dd/mmm/yyyy)', 'AMC-S007 (Version 2.0) 20MAR2018', '2', 'NCI Version Date 20MAR2018']['TABLE OF CONTENTS', 'SUMMARY OF CHANGES', 'i', 'AMC PROTOCOL SIGNATURE PAGE', '2', 'TABLE OF CONTENTS', '3', 'LIST OF TABLES AND FIGURES', '5', 'PROTOCOL ROSTER', '6', 'PROTOCOL SYNOPSIS', '7', 'PROTOCOL SCHEMA', '8', 'ABBREVIATIONS LIST', '9', '1.0', 'OBJECTIVES', '11', '1.1', 'Primary Objective', '11', '1.2', 'Secondary Objective', '11', '1.3', 'Exploratory Objective', '11', '2.0', 'BACKGROUND', '12', '2.1', 'Study Disease', '12', '2.2', 'Treatment Regimen', '12', '2.3', 'Study Design and Rationale', '12', '3.0', 'PARTICIPANT SELECTION', '14', '3.1', 'Eligibility Criteria', '14', '3.2', 'Exclusion Criteria', '15', '3.3', 'Number of Participants to be Enrolled', '16', '3.4', 'Participant Enrollment Procedures', '16', '4.0', 'TREATMENT PLAN', '17', '4.1', 'Treatment Administration', '17', '4.2', 'Concomitant Medication and Supportive Care Guidelines', '18', '4.3', 'Duration of Therapy', '19', '4.4', 'Duration of Follow Up', '20', '5.0', 'DOSING DELAYS/DOSE MODIFICATIONS', '21', '5.1', 'Dose Modifications for BV', '21', '5.2', 'Dose Modifications for Vincristine', '23', '5.3', 'Dose Modifications for Bleomycin', '24', '6.0', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', '26', '6.1', 'Adverse Events and Potential Risks Lists', '26', 'AMC-S007 (Version 2.0) 20MAR2018', '3', 'NCI Version Date 20MAR2018']['6.2', 'Classification of AEs by Severity and Relationship to Treatment', 'Administration', '26', '6.3', 'Expedited Adverse Event Reporting', '28', '6.4', 'Routine Adverse Event Reporting', '29', '6.5', 'Secondary Malignancy', '30', '6.6', 'Second Malignancy', '30', '7.0', 'PHARMACEUTICAL INFORMATION', '31', '7.1', 'Study Product Preparation', '31', '8.0', 'CLINICAL AND LABORATORY EVALUATIONS', '34', '8.1', 'Screening/Baseline Evaluations', '34', '8.2', 'Evaluations during Treatment', '34', '8.3', 'Treatment Discontinuation Evaluations', '35', '8.4', 'Final Evaluations, Off Study', '35', '9.0', 'MEASUREMENT OF EFFECT', '36', '9.1', 'Definition of Response', '36', '10.0', 'STATISTICAL CONSIDERATIONS', '39', '10.1', 'Study Design/Endpoints', '39', '10.2', 'Sample Size/Accrual Rate', '39', '11.0', 'ROLE OF DATA MANAGEMENT', '40', '11.1', 'CRF Instructions', '40', '11.2', 'Data Quality', '40', '11.3', 'Data Monitoring', '40', '12.0', 'ETHICAL AND REGULATORY CONSIDERATIONS', '41', '12.1', 'IRB Approval and Informed Consent', '41', '12.2', 'Changes to the Protocol', '41', '12.3', 'Women and Minorities', '41', '13.0 REFERENCES', '43', 'APPENDIX I: SCHEDULE OF EVALUATIONS', '44', 'APPENDIX II: PERFORMANCE STATUS SCALES', '45', 'APPENDIX III: AMC DATA AND SAFETY MONITORING PLAN', '46', 'APPENDIX IV: FACT-G QUESTIONNAIRE, VERSION 4, ENGLISH AND SWAHILI.49', 'AMC-S007 (Version 2.0) 20MAR2018', '4', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}